Quoin Pharmaceuticals, Ltd. (QNRX) stock: key figures, P/E, revenue and dividend
Health Care · ISIN US74907L1026
Quoin Pharmaceuticals, Ltd. financials
| Fiscal year | 2025 |
|---|---|
| EBIT | -15.80 m USD |
| Net income | -15.80 m USD |
Full history since 2015, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
More stocks
- Cytosorbents Corp (CTSO)
- Annovis Bio, Inc. (ANVS)
- CVRx, Inc. (CVRX)
- Creative Media & Community Trust Corp (CMCT)
- HG Holdings, Inc. (STLY)
- Picard Medical, Inc. (PMI)
- Skillsoft Corp. (SKIL)
- INTELLINETICS, INC. (INLX)
- WM TECHNOLOGY, INC. (MAPS)
- AmBase Corp (ABCP)
- Lipocine Inc. (LPCN)
- UPAY (UPYY)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.